Small Benefit Found in Treating Long COVID Fatigue

Researchers at the University College London (UCL) and University College London Hospitals (UCLH) have made significant progress in understanding the effects of two common medications on long COVID fatigue. A large-scale clinical trial, led by the institutions, has revealed that over-the-counter antihistamines and a prescription anti-inflammatory drug may provide a small benefit in alleviating long COVID-related fatigue among patients receiving specialized care. The study, which involved numerous participants receiving treatment from long COVID clinics, aimed to identify potential treatments for this debilitating symptom.

The trial found that both medications showed promise in reducing long COVID fatigue, although the effects were modest. Antihistamines, commonly used to treat allergies, appeared to have a small but significant impact on fatigue levels, while the prescription anti-inflammatory drug also demonstrated a positive effect. These findings are significant, as long COVID fatigue remains a major challenge for many individuals who have recovered from the initial COVID-19 infection. The results of the study provide valuable insights for healthcare providers and may inform the development of new treatments for this condition.

The study's outcomes highlight the need for further research into the management of long COVID fatigue. While the benefits of the two medications are encouraging, more work is required to fully understand their effects and to identify other potential treatments. As the global health community continues to grapple with the long-term consequences of COVID-19, these findings offer hope for improving the lives of individuals affected by long COVID fatigue.